以Ethos自动机器学习增强计划对局部晚期肺癌手动与知识库计划的基准评测
本研究纳入50例既往接受Eclipse手动计划的不可手术IIIA-IIIC期非小细胞肺癌患者,用15例迭代优化Ethos模板并对35例自动重新计划,与临床计划和RapidPlan计划进行基准比较。Ethos计划在靶区V95%覆盖和部分危及器官剂量上优于RapidPlan计划,但食管平均剂量和臂丛D0.03 cc更高,78%的Ethos计划被所有评审医师认为临床可接受。
要点
- 在处方靶区覆盖相等前提下,Ethos计划的原发灶和淋巴结PTV V95%覆盖优于RapidPlan计划(P<.001)。
- Ethos计划较RapidPlan计划降低肺GTV V5 Gy和食管D0.03 cc(P≤.003),但提高食管平均剂量和臂丛D0.03 cc(P<.001)。
- Ethos、临床和RapidPlan计划分别有80%、49%和51%符合ARTIA-Lung方案或达到「变异可接受」。
核心结论
- 标准Ethos模板生成的肺部放疗计划质量与RapidPlan计划相似,为Ethos自适应工作区自动计划生成提供了可行方法。
研究设计与样本
- 经机构审查委员会批准的回顾性研究,纳入50例既往接受手动Eclipse计划的不可手术IIIA-IIIC期非小细胞肺癌患者。
- 15例患者计划用于迭代优化ARTIA-Lung试验的Ethos计划模板,其余35例无干预自动重新计划。
- Ethos计划质量与临床计划及重新优化的知识库RapidPlan计划进行基准比较,采用标准剂量体积直方图指标、临床试验目标符合度和定性评审判定。
主要发现
- 在处方靶区覆盖相等前提下,Ethos计划的原发灶和淋巴结PTV V95%覆盖优于RapidPlan计划(P<.001)。
- Ethos计划较RapidPlan计划降低肺GTV V5 Gy和食管D0.03 cc(P≤.003),但提高食管平均剂量和臂丛D0.03 cc(P<.001)。
- Ethos、临床和RapidPlan计划分别有80%、49%和51%符合ARTIA-Lung方案或达到「变异可接受」。
- 三名放射肿瘤学家对Ethos计划定性评分,78%的计划被所有评审医师认为临床可接受,无计划需要重大修改。
关键数值与推荐
- Ethos计划原发灶和淋巴结PTV V95%覆盖优于RapidPlan计划(P<.001)。
- Ethos计划肺GTV V5 Gy和食管D0.03 cc低于RapidPlan计划(P≤.003)。
- Ethos计划食管平均剂量和臂丛D0.03 cc高于RapidPlan计划(P<.001)。
- Ethos、临床和RapidPlan计划符合ARTIA-Lung方案或达到「变异可接受」的比例分别为80%、49%和51%。
- 78%的Ethos计划被所有评审医师认为临床可接受,无计划需要重大修改。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Currently, there is insufficient guidance for standard fractionation lung planning using the Varian Ethos adaptive treatment planning system and its unique intelligent optimization engine. Here, we address this gap in knowledge by developing a methodology to automatically generate high-quality Ethos treatment plans for locally advanced lung cancer. METHODS AND MATERIALS: Fifty patients previously treated with manually generated Eclipse plans for inoperable stage IIIA-IIIC non-small cell lung cancer were included in this institutional review board-approved retrospective study. Fifteen patient plans were used to iteratively optimize a planning template for the Daily Adaptive vs Non-Adaptive External Beam Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung); the remaining 35 patients were automatically replanned without intervention. Ethos plan quality was benchmarked against clinical plans and reoptimized knowledge-based RapidPlan (RP) plans, then judged using standard dose-volume histogram metrics, adherence to clinical trial objectives, and qualitative review. RESULTS: Given equal prescription target coverage, Ethos-generated plans showed improved primary and nodal planning target volume V95% coverage (P < .001) and reduced lung gross tumor volume V5 Gy and esophagus D0.03 cc metrics (P ≤ .003) but increased mean esophagus and brachial plexus D0.03 cc metrics (P < .001) compared with RP plans. Eighty percent, 49%, and 51% of Ethos, clinical, and RP plans, respectively, were "per protocol" or met "variation acceptable" ARTIA-Lung planning metrics. Three radiation oncologists qualitatively scored Ethos plans, and 78% of plans were clinically acceptable to all reviewing physicians, with no plans receiving scores requiring major changes. CONCLUSIONS: A standard Ethos template produced lung radiation therapy plans with similar quality to RP plans, elucidating a viable approach for automated plan generation in the Ethos adaptive workspace.
引用
- Pogue JA, Cardenas CE, Harms J, et al. Benchmarking Automated Machine Learning-Enhanced Planning With Ethos Against Manual and Knowledge-Based Planning for Locally Advanced Lung Cancer. Adv Radiat Oncol. 2023. PMID: 37457825. doi:10.1016/j.adro.2023.101292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。